Ekaterina A. Stolbova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ekaterina A. Stolbova has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alexey A. Lagunin
Department for Bioinformatics, Institute of Biomedical Chemistry, 119121 Moscow, Russia
2 shared publications - Leonid A. Stolbov
Institute of Biomedical Chemistry, 10 Bldg. 8, Pogodinskaya Str., 119121 Moscow, Russia
2 shared publications - Olga Tarasova
Institute of Biomedical Chemistry, 10 Bldg. 8, Pogodinskaya Str., 119121 Moscow, Russia
2 shared publications - Vladimir V. Poroikov
Institute of Biomedical Chemistry
2 shared publications - Дмитрий Евгеньевич Киреев
Central Research Institute of Epidemiology, 111123 Moscow, Russia
2 shared publications A.B. Shemshura
Federal Budget Public Health Institution "Clinical Center of HIV/AIDS Treatment and Prevention" of the Ministry of Health of Krasnodar Region, 204/2, Mitrofana Sedina Str., 350000 Krasnodar, Russia
1 shared publication
Latest Publications
- 2 February 2026
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 278, 109268
A computational approach for classification of HIV drug resistance based on the self-consistent extreme classifier
- 2 February 2026
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 278, 109268
A computational approach for classification of HIV drug resistance based on the self-consistent extreme classifier
- Open Access
- 2 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10678
Early Transcriptomic Signatures of Immune Response Modulation Following Antiretroviral Therapy in HIV-Infected Patients
Human immunodeficiency virus (HIV) remains a global public health challenge. Antiretroviral therapy (ART) improves outcomes by suppressing viral replication and enabling immune recovery, yet the early molecular mechanisms of immune-related transcriptional change after ART remain insufficiently characterized. We enrolled eight ART-naïve male patients with HIV aged 18–35. Peripheral blood mononuclear cells (PBMCs) were collected before and after 24 weeks of combination ART (TDF, 3TC, DTG) and underwent bulk RNA-seq (Illumina HiSeq 1500, Illumina, Inc., San Diego, CA, USA). Differential expression was assessed with DESeq2 (paired design); gene set enrichment analysis (GSEA), principal component analysis (PCA), hierarchical clustering, and protein–protein interaction (PPI) networks (STRING/NetworkX) explored functional patterns and transcriptomic shifts. We identified 87 differentially expressed genes, including 67 downregulated interferon-stimulated genes (e.g., IFI44L, ISG15, STAT1) and 20 upregulated transcripts, mostly pseudogenes related to ribosomal proteins. Functional enrichment revealed suppression of type I interferon and other antiviral signaling pathways. PCA and hierarchical clustering indicated a post-ART transcriptional shift. These findings suggest that early immune recovery following ART involves downregulation of chronic interferon-driven activation. This observation may correspond to partial restoration of T-cell functional capacity, reduced immune exhaustion, and a rebalanced antiviral immune environment.
- 2 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10678
Open AccessEarly Transcriptomic Signatures of Immune Response Modulation Following Antiretroviral Therapy in HIV-Infected Patients
Human immunodeficiency virus (HIV) remains a global public health challenge. Antiretroviral therapy (ART) improves outcomes by suppressing viral replication and enabling immune recovery, yet the early molecular mechanisms of immune-related transcriptional change after ART remain insufficiently characterized. We enrolled eight ART-naïve male patients with HIV aged 18–35. Peripheral blood mononuclear cells (PBMCs) were collected before and after 24 weeks of combination ART (TDF, 3TC, DTG) and underwent bulk RNA-seq (Illumina HiSeq 1500, Illumina, Inc., San Diego, CA, USA). Differential expression was assessed with DESeq2 (paired design); gene set enrichment analysis (GSEA), principal component analysis (PCA), hierarchical clustering, and protein–protein interaction (PPI) networks (STRING/NetworkX) explored functional patterns and transcriptomic shifts. We identified 87 differentially expressed genes, including 67 downregulated interferon-stimulated genes (e.g., IFI44L, ISG15, STAT1) and 20 upregulated transcripts, mostly pseudogenes related to ribosomal proteins. Functional enrichment revealed suppression of type I interferon and other antiviral signaling pathways. PCA and hierarchical clustering indicated a post-ART transcriptional shift. These findings suggest that early immune recovery following ART involves downregulation of chronic interferon-driven activation. This observation may correspond to partial restoration of T-cell functional capacity, reduced immune exhaustion, and a rebalanced antiviral immune environment.
- Open Access
- 30 January 2025
- Published by Elsevier in SSRN Electronic Journal
A Computational Approach for Classification of HIV Drug Resistance Based on the Self-Consisted Extreme Classifier
The development of viral resistance can significantly reduce the effectiveness of therapy. Human immunodeficiency virus type 1 is the cause of chronic immune dysfunction, leading to the development of co-infections and serious complications. Despite worldwide progress and consolidated efforts to overcome HIV drug resistance, the development of novel approaches to rational drug therapy of HIV infection is still needed. Our study is dedicated to the development of a novel computational ML-driven approach for the ternary classification of HIV protease, reverse transcriptase, and integrase sequences. The approach is based on the Self-Consisted Extreme Classifier (SCEC). The average prediction accuracy (AUC ROC) for one versus other models is about 0.88, which is comparable when to classes are compared in binary classification. We tested our approach in a clinical task and performed prospective validation for eight sequences of HIV protease and reverse transcriptase obtained from treatment-naive HIV-positive male patients. We performed a prediction and compared the results with the therapeutic outcome, in particular, with the viral load decline at 24 weeks. The results of the prospective validation are generally consistent with the results of the therapeutic outcome and confirm the possibility of using the developed approach for the selection of the most appropriate therapeutic regimens.
- 30 January 2025
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Computational Approach for Classification of HIV Drug Resistance Based on the Self-Consisted Extreme Classifier
The development of viral resistance can significantly reduce the effectiveness of therapy. Human immunodeficiency virus type 1 is the cause of chronic immune dysfunction, leading to the development of co-infections and serious complications. Despite worldwide progress and consolidated efforts to overcome HIV drug resistance, the development of novel approaches to rational drug therapy of HIV infection is still needed. Our study is dedicated to the development of a novel computational ML-driven approach for the ternary classification of HIV protease, reverse transcriptase, and integrase sequences. The approach is based on the Self-Consisted Extreme Classifier (SCEC). The average prediction accuracy (AUC ROC) for one versus other models is about 0.88, which is comparable when to classes are compared in binary classification. We tested our approach in a clinical task and performed prospective validation for eight sequences of HIV protease and reverse transcriptase obtained from treatment-naive HIV-positive male patients. We performed a prediction and compared the results with the therapeutic outcome, in particular, with the viral load decline at 24 weeks. The results of the prospective validation are generally consistent with the results of the therapeutic outcome and confirm the possibility of using the developed approach for the selection of the most appropriate therapeutic regimens.
- Open Access
Quantitative Prediction of Human Immunodeficiency Virus Drug Resistance
Drug resistance of pathogens, including viruses, is one of the reasons for decreased efficacy of therapy. Considering the impact of HIV type 1 (HIV-1) on the development of progressive immune dysfunction and the rapid development of drug resistance, the analysis of HIV-1 resistance is of high significance. Currently, a substantial amount of data has been accumulated on HIV-1 drug resistance that can be used to build both qualitative and quantitative models of HIV-1 drug resistance. Quantitative models of drug resistance can enrich the information about the efficacy of a particular drug in the scheme of antiretroviral therapy. In our study, we investigated the possibility of developing models for quantitative prediction of HIV-1 resistance to eight protease inhibitors based on the analysis of amino acid sequences of HIV-1 protease for 900 virus variants. We developed random forest regression (RFR), support vector regression (SVR), and self-consistent regression (SCR) models using binary vectors containing values from 0 or 1, depending on the presence of a specific peptide fragment in each amino acid sequence as independent variables, while fold ratio, reflecting the level of resistance, was the predicted variable. The SVR and SCR models showed the highest predictive performances. The models built demonstrate reasonable performances for eight out of nine (R2 varied from 0.828 to 0.909) protease inhibitors, while R2 for predicting tipranavir fold ratio was lower (R2 was 0.642). We believe that the developed approach can be applied to evaluate drug resistance of molecular targets of other viruses where appropriate experimental data are available.
Open AccessQuantitative Prediction of Human Immunodeficiency Virus Drug Resistance
Drug resistance of pathogens, including viruses, is one of the reasons for decreased efficacy of therapy. Considering the impact of HIV type 1 (HIV-1) on the development of progressive immune dysfunction and the rapid development of drug resistance, the analysis of HIV-1 resistance is of high significance. Currently, a substantial amount of data has been accumulated on HIV-1 drug resistance that can be used to build both qualitative and quantitative models of HIV-1 drug resistance. Quantitative models of drug resistance can enrich the information about the efficacy of a particular drug in the scheme of antiretroviral therapy. In our study, we investigated the possibility of developing models for quantitative prediction of HIV-1 resistance to eight protease inhibitors based on the analysis of amino acid sequences of HIV-1 protease for 900 virus variants. We developed random forest regression (RFR), support vector regression (SVR), and self-consistent regression (SCR) models using binary vectors containing values from 0 or 1, depending on the presence of a specific peptide fragment in each amino acid sequence as independent variables, while fold ratio, reflecting the level of resistance, was the predicted variable. The SVR and SCR models showed the highest predictive performances. The models built demonstrate reasonable performances for eight out of nine (R2 varied from 0.828 to 0.909) protease inhibitors, while R2 for predicting tipranavir fold ratio was lower (R2 was 0.642). We believe that the developed approach can be applied to evaluate drug resistance of molecular targets of other viruses where appropriate experimental data are available.